Oct 2 (Reuters) – Chinese biotech company Abogen said on Friday it signed a licensing and option agreement worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy.
(Reporting by Ruchika Khanna in Bengaluru; Editing by Subhranshu Sahu)
Comments